

# CITATION REPORT

List of articles citing

## Cardiovascular outcome trials of the newer anti-diabetic medications

DOI: 10.1016/j.pcad.2019.08.003

Progress in Cardiovascular Diseases, 2019, 62, 342-348.

**Source:** <https://exaly.com/paper-pdf/72560530/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45, 883-891	2.2	18
19	Statistics 2020 at progress in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 534-535	8.5	0
18	Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 154	8.7	8
17	Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet. <i>Heliyon</i> , <b>2020</b> , 6, e05431	3.6	3
16	Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2020</b> , 19, 1873-1878	2.5	2
15	Estimating the attributable risk of vascular disorders in different ranges of fasting plasma glucose and assessing the effectiveness of anti-diabetes agents on risk reduction; questioning the current diagnostic criteria. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2020</b> , 19, 1423-1430	2.5	2
14	Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2020</b> , 27, 1139-1140	4	
13	PCVD 2020. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 74-75	8.5	0
12	Bariatric surgery is beneficial for cardiovascular in type 2 diabetes patients. <i>Obesity Medicine</i> , <b>2020</b> , 18, 100231	2.6	1
11	A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 65-79	2.9	26
10	Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies. <i>Maturitas</i> , <b>2021</b> , 143, 118-126	5	4
9	Editor-in-chief eight years at Progress in Cardiovascular Diseases. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 64, 138-139	8.5	0
8	Potential Role of Melatonin as an Adjuvant for Atherosclerotic Carotid Arterial Stenosis. <i>Molecules</i> , <b>2021</b> , 26,	4.8	2
7	Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. <i>Annales D'Endocrinologie</i> , <b>2021</b> , 82, 99-106	1.7	1
6	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives. <i>Clinical Science</i> , <b>2021</b> , 135, 1369-1387	6.5	2
5	Cardiovascular Statistics 2021. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 67, 114-115	8.5	0
4	Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 1418-1426	3.5	5

- 3 Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.. *Frontiers in Pharmacology*, **2021**, 12, 759262 5.6 ○
- 2 Pathophysiological Links Between Diabetes and Cardiovascular Diseases: at the Biochemical and Molecular Levels. **2022**, 191-229 ○
- 1 Person-Centered Cardiology. **2023**, 501-538 ○